AOD-9604 vs Tesamorelin

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

AOD-9604

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.

Full details →

Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

Full details →

Side-by-Side Comparison

AspectAOD-9604Tesamorelin
MechanismStimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors.Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue.
Typical DosageResearch dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg.FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules.
AdministrationSubcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects.Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening.
Side EffectsGenerally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH.Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose.
Best For

What They Have in Common

Both AOD-9604 and Tesamorelin are commonly used for:

Key Differences

Ready to Learn More?